A prospective study to assess emergence and transmissibility of drug resistance to neuraminidase inhibitor following treatment of children and adults with acute pandemic influenza - antiviral resistance to influenza

niversity Hospitals Leicester0 个研究点开始时间: 2009年5月29日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Inclusion criteria
•1. Boys and girls must satisfy the following to qualify for the study:aged between >1 and 16 years (or any age eligible for treatment)and have Parents or legal guardians willing to give written informed consent
•2. Subjects aged over 16 years:
•3. presenting an acute febrile illness including
•oacute respiratory tract illness,
•ofebrile seizure
•ofebrile gastrointestinal illness
•oacute febrile illness with temp >38oC
•4. Willing for post treatment sampling to be conducted
•5. Able to adhere with oseltamivir treatment (5 days b.d dosing)
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Exclusion criteria
•unable to obtain informed consent
•conditions presenting with:
•oknown bacterial aetiology
•onon-respiratory conditions with known aetiology
•allergy to oseltamivir or zanamivir
•presence of underlying condition requiring dose alteration of oseltamivir e.g. severe renal failure
•Concomitant therapy requiring oseltamivir dose alteration including methotrexate and probenecid
•inability to obtain nasopharyngeal sample for analysis
•concurrent enrollment in any therapeutic intervention studies

发起方

niversity Hospitals Leicester